BAJAJ BROKING
Biocon Ltd announced its subsidiary’s approval from NMPA China for Tacrolimus capsules. The drug will strengthen its portfolio and bolster its global market presence. Biocon Ltd share price rose by 1.13% post-announcement.
Biocon Pharma Ltd, a wholly owned subsidiary of Biocon Ltd, has received approval from the National Medical Products Administration (NMPA) in China for its Tacrolimus capsules in strengths of 0.5mg, 1mg, and 5mg. Tacrolimus, an immunosuppressant drug, is primarily used to prevent organ rejection in transplant patients by modulating the immune system.
Also read: Avenue Supermarts Reports 17.5% Revenue Growth in Q3 FY25
Approval Scope: Tacrolimus capsules approved in 0.5mg, 1mg, and 5mg strengths.
Therapeutic Use: Prevents organ rejection in transplant patients.
Global Presence: Enhances Biocon’s portfolio in complex drugs.
Also read: Wockhardt’s Miqnaf Gains CDSCO Approval for CABP Treatment
Metric | Q2 FY25 | Q2 FY24 | Change (YoY) |
Net Profit | ₹27.1 crore | ₹172 crore | -84.2% |
Revenue from Operations | ₹3,590.4 crore | ₹3,462 crore | +3.7% |
EBITDA | ₹685.5 crore | ₹741.3 crore | -7.6% |
This approval marks a strategic milestone for Biocon, as it further strengthens the company’s portfolio of complex drugs and expands its reach in the global pharmaceutical market. With the Chinese market’s regulatory clearance, Biocon can expedite the commercialisation of Tacrolimus capsules in the region.
Following the announcement, Biocon Ltd share price increased by 1.13%, closing at ₹372.95 on the BSE. This reflects investor confidence in Biocon’s ongoing efforts to expand its global footprint and enhance its portfolio.
Biocon’s NMPA approval for Tacrolimus capsules demonstrates its commitment to innovation and global expansion. The move further cements Biocon’s position as a leader in the biotechnology and pharmaceutical sectors, with promising prospects for future growth.
Also read: IRFC Partners REMCL to Fund Renewable Energy for Railways
Do you have a trading account app or demat account app?
You can open an account with Bajaj Broking in minutes.
Download the Bajaj Broking app now from Play Store or App Store.
Disclaimer: Investments in the securities market are subject to market risk, read all related documents carefully before investing.
This content is for educational purposes only. Securities quoted are exemplary and not recommendatory.
For All Disclaimers Click Here: https://bit.ly/3Tcsfuc
Share this article:
Level up your stock market experience: Download the Bajaj Broking App for effortless investing and trading